Roche Holding AG (RHHBY) Stock: Rises After Strong Q3 Sales and Major FDA Approvals

TLDR Roche stock rises 1.18% as third-quarter sales climb 7% at constant exchange rates. Roche reports CHF 46.5 billion in nine-month sales, fueled by key medicines. FDA approvals for Tecentriq and Enspryng expand Roche’s treatment portfolio. Roche’s top five medicines generate CHF 16.8 billion, up 12% at constant rates. Roche maintains its 2026 growth outlook [...]

The post Roche Holding AG (RHHBY) Stock: Rises After Strong Q3 Sales and Major FDA Approvals appeared first on Blockonomi.